PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
Phosphoinositide kinases (PIKs) are a group of lipid kinases that are important upstream activators of various significant signaling pathways. Hyperactivation of the PI3K/AKT/mTOR pathways—either via mutations or genomic amplification—confers key oncogenic activity, essential for...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/1/93 |
| _version_ | 1797699895538221056 |
|---|---|
| author | Ali Alqahtani Hazem S. K. Ayesh Hafez Halawani |
| author_facet | Ali Alqahtani Hazem S. K. Ayesh Hafez Halawani |
| author_sort | Ali Alqahtani |
| collection | DOAJ |
| description | Phosphoinositide kinases (PIKs) are a group of lipid kinases that are important upstream activators of various significant signaling pathways. Hyperactivation of the PI3K/AKT/mTOR pathways—either via mutations or genomic amplification—confers key oncogenic activity, essential for the development and progression of several solid tumors. Alterations in the <i>PIK3CA</i> gene are associated with poor prognosis of solid malignancies. Although the literature reports contradictory prognostic values of <i>PIK3CA</i> in aggressive cancers, most of the available data highlight the important role of <i>PIK3CA</i> mutation in mediating tumorigenesis via increased signaling of the PI3K/AKT/mTOR survival pathway. Several inhibitors of PI3K/AKT/mTOR pathways are investigated as potential therapeutic options in solid malignancies. This article reviews the role of <i>PIK3CA</i> mutations and inhibitors of PI3K/AKT/mTOR pathways in major cancer types and examines its association with clinicopathological parameters and prognosis. |
| first_indexed | 2024-03-12T04:15:33Z |
| format | Article |
| id | doaj.art-e3785164151f4eb992b42f3986fd2e92 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T04:15:33Z |
| publishDate | 2019-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e3785164151f4eb992b42f3986fd2e922023-09-03T10:41:15ZengMDPI AGCancers2072-66942019-12-011219310.3390/cancers12010093cancers12010093PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and PrognosisAli Alqahtani0Hazem S. K. Ayesh1Hafez Halawani2Department of Internal Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USADepartment of Internal Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USADepartment of Oncology, Cabrini Cancer Center, Alexandria, LA 71301, USAPhosphoinositide kinases (PIKs) are a group of lipid kinases that are important upstream activators of various significant signaling pathways. Hyperactivation of the PI3K/AKT/mTOR pathways—either via mutations or genomic amplification—confers key oncogenic activity, essential for the development and progression of several solid tumors. Alterations in the <i>PIK3CA</i> gene are associated with poor prognosis of solid malignancies. Although the literature reports contradictory prognostic values of <i>PIK3CA</i> in aggressive cancers, most of the available data highlight the important role of <i>PIK3CA</i> mutation in mediating tumorigenesis via increased signaling of the PI3K/AKT/mTOR survival pathway. Several inhibitors of PI3K/AKT/mTOR pathways are investigated as potential therapeutic options in solid malignancies. This article reviews the role of <i>PIK3CA</i> mutations and inhibitors of PI3K/AKT/mTOR pathways in major cancer types and examines its association with clinicopathological parameters and prognosis.https://www.mdpi.com/2072-6694/12/1/93solid malignancy<i>pik3ca</i>mutationoverall survivalpi3k/akt/mtor pathway |
| spellingShingle | Ali Alqahtani Hazem S. K. Ayesh Hafez Halawani PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis Cancers solid malignancy <i>pik3ca</i> mutation overall survival pi3k/akt/mtor pathway |
| title | PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis |
| title_full | PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis |
| title_fullStr | PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis |
| title_full_unstemmed | PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis |
| title_short | PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis |
| title_sort | pik3ca gene mutations in solid malignancies association with clinicopathological parameters and prognosis |
| topic | solid malignancy <i>pik3ca</i> mutation overall survival pi3k/akt/mtor pathway |
| url | https://www.mdpi.com/2072-6694/12/1/93 |
| work_keys_str_mv | AT alialqahtani pik3cagenemutationsinsolidmalignanciesassociationwithclinicopathologicalparametersandprognosis AT hazemskayesh pik3cagenemutationsinsolidmalignanciesassociationwithclinicopathologicalparametersandprognosis AT hafezhalawani pik3cagenemutationsinsolidmalignanciesassociationwithclinicopathologicalparametersandprognosis |